Related Experiment Videos
The plasma concentration and LDL-C relationship in patients receiving ezetimibe
F Ezzet1, D Wexler, P Statkevich
1Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
Journal of Clinical Pharmacology
|September 11, 2001
Summary
Ezetimibe effectively lowers LDL cholesterol by inhibiting intestinal absorption. Achieving over 15% LDL-C reduction requires maintaining plasma ezetimibe concentrations above 15 ng/ml, with the 10 mg daily dose being optimal.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Ezetimibe is a selective inhibitor of intestinal cholesterol absorption.
- It significantly reduces low-density lipoprotein cholesterol (LDL-C).
Purpose of the Study:
- To determine the relationship between plasma ezetimibe concentrations and LDL-C lowering.
- To identify optimal therapeutic ezetimibe dosing for hypercholesterolemia.
Main Methods:
- Analysis of data from two Phase II double-blind placebo-controlled studies.
- Utilized Emax and regression models to correlate ezetimibe concentrations with LDL-C reduction.
- Administered daily ezetimibe doses ranging from 0.25 to 10 mg for 12 weeks.
Main Results:
- Ezetimibe concentrations showed a significant correlation with the percentage change in LDL-C from baseline.
- Concentrations > 15 ng/ml were associated with >20% LDL-C reduction.
- A daily 10 mg dose demonstrated the highest likelihood of achieving target trough concentrations (>15 ng/ml).
Conclusions:
- Plasma ezetimibe concentrations are directly related to LDL-C lowering efficacy.
- Maintaining trough concentrations >15 ng/ml is necessary for >15% LDL-C reduction.
- A daily 10 mg dose of ezetimibe is confirmed as optimal for hypercholesterolemia treatment.